KR101947093B1 - 루푸스를 확인 및 치료하기 위한 방법 및 조성물 - Google Patents

루푸스를 확인 및 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR101947093B1
KR101947093B1 KR1020177009940A KR20177009940A KR101947093B1 KR 101947093 B1 KR101947093 B1 KR 101947093B1 KR 1020177009940 A KR1020177009940 A KR 1020177009940A KR 20177009940 A KR20177009940 A KR 20177009940A KR 101947093 B1 KR101947093 B1 KR 101947093B1
Authority
KR
South Korea
Prior art keywords
snps
gene
lupus
snp
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177009940A
Other languages
English (en)
Korean (ko)
Other versions
KR20170042831A (ko
Inventor
티모시 더블유. 버렌스
제프리 홈
워드 에이. 오트만
로버트 로얄 그라함
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20170042831A publication Critical patent/KR20170042831A/ko
Application granted granted Critical
Publication of KR101947093B1 publication Critical patent/KR101947093B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
    • C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
    • C12Q2533/101—Primer extension
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Theoretical Computer Science (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177009940A 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물 Active KR101947093B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93915607P 2007-05-21 2007-05-21
US60/939,156 2007-05-21
US1328307P 2007-12-12 2007-12-12
US61/013,283 2007-12-12
PCT/US2008/064430 WO2008144761A2 (en) 2007-05-21 2008-05-21 Methods and compositions for identifying and treating lupus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157032728A Division KR101729431B1 (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197003511A Division KR20190015629A (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20170042831A KR20170042831A (ko) 2017-04-19
KR101947093B1 true KR101947093B1 (ko) 2019-02-12

Family

ID=40122294

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177009940A Active KR101947093B1 (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물
KR1020197003511A Withdrawn KR20190015629A (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물
KR1020157032728A Active KR101729431B1 (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물
KR1020097026436A Active KR101651678B1 (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197003511A Withdrawn KR20190015629A (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물
KR1020157032728A Active KR101729431B1 (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물
KR1020097026436A Active KR101651678B1 (ko) 2007-05-21 2008-05-21 루푸스를 확인 및 치료하기 위한 방법 및 조성물

Country Status (14)

Country Link
US (1) US20110046094A1 (enExample)
EP (3) EP2612924B1 (enExample)
JP (4) JP5728226B2 (enExample)
KR (4) KR101947093B1 (enExample)
CN (3) CN103298950B (enExample)
AU (1) AU2008254582A1 (enExample)
BR (1) BRPI0811930B8 (enExample)
CA (1) CA2690608C (enExample)
ES (1) ES2661249T3 (enExample)
HK (1) HK1255086A1 (enExample)
IL (1) IL201949A0 (enExample)
MX (3) MX343167B (enExample)
RU (1) RU2009147281A (enExample)
WO (1) WO2008144761A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008254582A1 (en) * 2007-05-21 2008-11-27 Genentech, Inc. Methods and compositions for identifying and treating lupus
CA2736373A1 (en) * 2008-09-26 2010-04-01 Timothy W. Behrens Methods for treating, diagnosing, and monitoring lupus
US20100105061A1 (en) * 2008-10-29 2010-04-29 University Of Southern California Autoimmune genes identified in systemic lupus erythematosus (sle)
AU2010220397A1 (en) * 2009-03-03 2011-07-28 Merck Serono S.A. BANK1 related SNPS and SLE and/or MS susceptibility
CN113025703A (zh) * 2009-10-07 2021-06-25 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控狼疮的方法
WO2011109338A1 (en) * 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
EP2673372A4 (en) * 2011-02-10 2014-11-19 Genqual Corp PROCESS FOR PROGNOSIS AND ADMINISTRATION OF INFLAMMATORY DISEASES
US20130317006A1 (en) 2012-05-24 2013-11-28 Amy Yasko Use of polymorphisms for identifying individuals at risk of developing autism
WO2015081052A1 (en) 2013-11-27 2015-06-04 Yasko Amy Use of polymorphisms for identifying individuals at risk of developing autism
JP2018518203A (ja) * 2015-06-24 2018-07-12 オックスフォード バイオダイナミックス リミテッド エピジェネティックな染色体相互作用
CN110459312B (zh) * 2018-05-07 2024-01-12 深圳华大生命科学研究院 类风湿性关节炎易感位点及其应用
US20230054595A1 (en) * 2019-12-18 2023-02-23 The Children's Hospital Of Philadelphia Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same
KR20240021336A (ko) 2022-08-09 2024-02-19 심재홍 수액 채취장치의 냉각기 구조
CN116030889A (zh) * 2023-02-16 2023-04-28 复旦大学 一种线粒体异质性分布中分配差异率计算的模型化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162180A1 (en) * 2002-02-26 2003-08-28 New York Society For Ruptured And Crippled Maintaining The Hospital Human FcgammaRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
EP1313880A2 (en) 2000-05-30 2003-05-28 PE Corporation (NY) Methods for detecting target nucleic acids using coupled ligation and amplification
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
CA2426540A1 (en) * 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
US7205106B1 (en) * 2001-07-20 2007-04-17 Roche Molecular Systems, Inc. Association of polymorphisms in IL4-related genes with autoimmune disease
JP2003061677A (ja) * 2001-08-28 2003-03-04 Olympus Optical Co Ltd 全身性エリテマトーデスの感受性遺伝子およびその使用
US20030119004A1 (en) * 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
CA2477761A1 (en) * 2002-03-01 2003-09-12 Ravgen, Inc. Methods for detection of genetic disorders
WO2004083403A2 (en) * 2003-03-18 2004-09-30 Applera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2005086872A2 (en) * 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
EP1863927A2 (en) * 2005-03-15 2007-12-12 Ares Trading S.A. Compositions and methods for treating and diagnosing inflammatory disorders
EP1945800B1 (en) 2005-08-05 2012-03-14 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
AU2008254582A1 (en) * 2007-05-21 2008-11-27 Genentech, Inc. Methods and compositions for identifying and treating lupus
CA2736373A1 (en) * 2008-09-26 2010-04-01 Timothy W. Behrens Methods for treating, diagnosing, and monitoring lupus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162180A1 (en) * 2002-02-26 2003-08-28 New York Society For Ruptured And Crippled Maintaining The Hospital Human FcgammaRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof

Also Published As

Publication number Publication date
CN103298950B (zh) 2015-01-21
HK1209459A1 (en) 2016-04-01
CA2690608C (en) 2020-07-21
HK1255086A1 (en) 2019-08-02
JP6080059B2 (ja) 2017-02-15
AU2008254582A1 (en) 2008-11-27
KR20150133861A (ko) 2015-11-30
EP3318643A2 (en) 2018-05-09
BRPI0811930B8 (pt) 2021-05-25
MX378733B (es) 2025-03-10
CN104593488A (zh) 2015-05-06
CN103298950A (zh) 2013-09-11
EP2612924A3 (en) 2013-10-23
HK1189246A1 (en) 2014-05-30
CA2690608A1 (en) 2008-11-27
KR101729431B1 (ko) 2017-04-21
EP2158335A2 (en) 2010-03-03
JP2018126146A (ja) 2018-08-16
KR20190015629A (ko) 2019-02-13
MX343167B (es) 2016-10-26
EP3318643A3 (en) 2018-06-20
EP2612924B1 (en) 2017-12-20
US20110046094A1 (en) 2011-02-24
KR20100021612A (ko) 2010-02-25
ES2661249T3 (es) 2018-03-28
IL201949A0 (en) 2010-06-16
BRPI0811930A2 (pt) 2014-11-25
CN108753946A (zh) 2018-11-06
KR101651678B1 (ko) 2016-08-26
WO2008144761A2 (en) 2008-11-27
MX2009012531A (es) 2009-12-03
JP2015164426A (ja) 2015-09-17
WO2008144761A3 (en) 2009-07-02
CN104593488B (zh) 2018-06-12
JP2017035088A (ja) 2017-02-16
EP2612924A2 (en) 2013-07-10
BRPI0811930B1 (pt) 2019-11-05
RU2009147281A (ru) 2011-06-27
MX353428B (es) 2018-01-12
JP2010528590A (ja) 2010-08-26
JP5728226B2 (ja) 2015-06-03
KR20170042831A (ko) 2017-04-19

Similar Documents

Publication Publication Date Title
KR101947093B1 (ko) 루푸스를 확인 및 치료하기 위한 방법 및 조성물
US10053734B2 (en) Methods for treating, diagnosing, and monitoring lupus
CN102803509B (zh) 用于治疗、诊断和监控狼疮的方法
HK1209459B (zh) 用於鑒定和治療狼瘡的方法和組合物
HK1189246B (en) Methods and compositions for identifying and treating lupus
HK1237003A1 (en) Methods for treating, diagnosing, and monitoring lupus
HK1176384B (en) Methods for treating, diagnosing, and monitoring lupus

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170412

Application number text: 1020157032728

Filing date: 20151116

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170512

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170703

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180513

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20181105

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190201

Application number text: 1020157032728

Filing date: 20151116

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190201

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190207

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240130

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250203

Start annual number: 7

End annual number: 7